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Abstract: We previously isolated aaptamine, a benzonaphthyridine alkaloid, from marine 
sponge Aaptos suberitoids. In this study, we investigated the anti-proliferative effect of 
aaptamine on chronic myeloid leukemia (CML) K562 cells. Aaptamine inhibited growth of 
K562 with a GI50 as 10 μM, and arrested cell cycle at G2/M phase. Western blot analysis 
indicated that aaptamine induced p21 expression in K562 cells. Moreover, p21 promoter 
was activated by aaptamine treatment in p21 transfected K562 cells. Since K562 is p53 
negative, aaptamine was demonstrated to be a p53-independent p21 inducer in CML cells.  
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1. Introduction 
Chronic  myelogenous leukemia (CML) is  a  myeloproliferative disease originating from a 
constitutively active tyrosine kinase termed Bcr-Abl, which is expressed by an oncogene resulting 
from a reciprocal translocation between chromosome 9 and chromosome 22  [1].  As the first   
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molecular-targeted small molecular anticancer drug, Glivec (imatinib), an inhibitor targeting Bcr-Abl, 
has been used to treat CML. In the last decade, Glivec exhibited remarkable efficacy in treatment of 
CML patients particularly in chronic phase [2].  However,  resistance in some patients has been 
frequently  reported  [3]. The resistance is  mainly  caused by mutations  in  the  Abl  tyrosine kinase 
domain, which affects binding of Glivec and its analogues [4,5]. Therefore, development  of  an 
alternative drug to Glivec for CML treatment has been expected.  
Discovery of antitumor drugs from marine organisms has made great progress in recent years. 
Trabectedin was the first antitumor drug which was approved in European Union in 2007 [6]. 
Moreover, Halaven
R (eribulin mesylate), an analogue of halchondrin B isolated from marine sponge 
Halichondria Okadai, was approved by FDA of USA for the treatment of metastatic breast cancer on 
15 November 2010.  
Aiming for discovery of new antitumor drug candidates or seed compounds from marine organisms, 
we have been carrying out bioassay guided isolation of compounds from marine sponges or screening 
of the isolated compounds with novel assay methods [7–12].  We  previously isolated aaptamine   
(Figure 1) from the marine sponge of Aaptos suberitoides and reported the p21-transactivating activity 
on human osteosarcoma MG63 cells [7]. Whether this compound has anti-proliferative effect on CML 
or not remained unclear. Recently we investigated the in vitro activity of aaptamine on proliferation, 
cell cycle progression, etc., in K562 cells.  
Figure 1. Chemical structure of aaptamine.  
 
2. Results and Discussion 
2.1. Aaptamine Inhibited the Proliferation of K562 Cells 
We first examined the anti-proliferative activity of aaptamine on K562 cells by use of WST-8 assay 
as described by us previously [13]. After treatment with various concentrations of aaptamine for 48 h, 
remaining cell number was measured. As shown in Figure 2, aaptamine inhibited the growth of K562 
cells dose-dependently. The GI50 (the concentration that causes 50% inhibition of the growth of cells) 
was calculated to be 10 μM by Graphpad Prism 4. 
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Figure 2. Effect of aaptamine on growth of K562 cells. K562 cells were incubated with 
various concentrations of aaptamine in 96-well plate at 37 °C. Two days later, WST-8 
solution was added and the cells were further incubated for 3 h followed by measurement 
of the absorbance (450 nm) with microplate spectrophotometer. The number of remaining 
cells after treatment was calculated using the following formula: Cell number (% control) = 
100 × (absorbance of a given sample − absorbance of Blank well)/(absorbance of Control 
well − absorbance of Blank well), where the Blank well contained medium only and the 
Control well contained cells without aaptamine. 
 
2.2. Aaptamine Arrested the Cell Cycle of K562 Cells at G2/M Phase 
Since cell cycle progression is required for cell growth and proliferation, we investigated the effect 
of aaptamine on the cell cycle progression in K562 cells. The cells were treated with 0, 20 and 100 μM 
of aaptamine for 48 h and the cell cycle was analyzed by flow cytometer. As shown in Figure 3, cells 
accumulating in G2/M phase increased while those in G1 phase decreased dose-dependently; 
particularly, 100 μM of aaptamine accumulates the K562 cells in G2/M phase to 49.6%, suggesting 
that aaptamine mainly arrests K562 cells at the G2/M phase. In addition, there was no obvious sub-G1 
phase, suggesting no obvious apoptosis induced by aaptamine treatment. 
Figure 3. Effect of aaptamine on the cell cycle of K562 cells. K562 cells was incubated 
with various concentrations of aaptamine for 48 h. The collected cells were dyed with 
DNA-Prep Reagents Kit and analyzed by flow cytometer (λex = 493 nm, λem = 630 nm). 
The analysis was quantified by ModFit software.  
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2.3. Aaptamine Induced p21 Expression in K562 Cells 
Cell cycle progression is promoted by Cdk  (cyclin dependent kinase)-cyclin  complexes and 
inhibited by cyclin-dependent kinase inhibitors (CKIs), which suppress kinase activity of Cdk-cyclin 
complexes. As a well known CKI, p21 is mainly controlled by diverse mechanisms in a p53-dependent 
manner. P53 was known to be loss-of-function mutated in over 50% of human cancer cells [14,15], as 
a major event of carcinogenesis. Therefore, the agents that induce an increase of p21 expression in a 
p53-independent manner are considered to contribute to cancer chemotherapy or prevention.  
So we examined whether aaptamine could induce p21 expression in K562 cells, which are known to 
be p53 negative. K562 cells were treated with 100 μM of aaptamine and incubated for 0, 24, and 48 h, 
respectively. The cells were harvested for western blot analysis. As shown in Figure 4, the expression 
of p21 was not detectable  before treatment.  After treatment with aaptamine,  p21 expression was 
induced and increased time-dependently within 48 h. 10 μM of aaptamine led to similar effect on p21 
expression, but less obvious than 100 μM. 
Figure 4. Aaptamine induced p21 expression in K562 cells. The cells were incubated with 
100 μM of aaptamine for the indicated times. Cell lysates were prepared and applied to  
4–20%  SDS-Polyacrylamide gel electrophoresis (SDS PAGE). After being transferred 
to polyvinylidene difluoride (PVDF)  membrane, the blots were exposed to   
anti-Cip1/WAF-1/p21 or anti-β-actin, and then to anti-mouse horseradish peroxidase (HRP) 
conjugated IgG antibody. 
 
2.4. Aaptamine Activated p21 Promoter in K562 Cells 
To investigate whether the induction of p21 expression is caused by the activation of p21 promoter, 
the  activating  effect  of aaptamine  on  p21 promoter  in  K562  cells  transfected  with  a human p21 
promoter-luciferase fusion plasmid  (pWWP)  was examined.  The  relative luciferase  activity  of the 
aaptamine-treated cells indicates an intensity of the activation of p21 promoter in comparison with that 
of the untreated cells. As shown in Figure 5, aaptamine activated p21 promoter dose-dependently and 
increased the luciferase activity to 12.5 fold at 100 μM. Since K562 cell is p53 negative cell, the 
activation of p21 promoter and the above-mentioned p21 expression induction is supposed to be   
p53-independent. 
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Figure 5. Activation of p21 promoter in K562 cells. K562 cells were transfected with the 
human p21 promoter-luciferase fusion plasmid (pWWP), followed by treatment with various 
concentrations of aaptamine for 24 h, and then analyzed by luciferase assay. Fold increase 
of luciferase activity  by aaptamine was calculated in comparison with the luciferase 
activity of the untreated cells. The result represents three independent experiments. 
 
3. Experimental Section 
3.1. Materials  
WST-8 assay kit was purchased from Kishida Chemicals.  DNA-Prep Reagents Kit was from 
Coulter Co., Ltd. Polyvinylidene difluoride (PVDF) membrane was purchased from Amersham 
Pharmacia Biotec UK, Ltd. Gel cassettes (4–20%) were from Daiichi Pure Chemicals Co., Ltd.   
Anti-Cip1/WAF-1/p21  antibody was from Milipore.  Anti-β-actin  was from Sigma.Anti-mouse  
HRP-conjugated antibody was from Nacalai Tesque Inc. PWWP, a human p21 promoter-luciferase 
fusion plasmid, was prepared as described by us previously [7]. 
3.2. Isolation and Identification of Aaptamine 
Aaptamine was isolated from the marine sponge Aaptos suberitoids as described previously [8]. 
The structure was identified by comparison of the mass and NMR data with those reported. 
3.3. Cell Culture 
Human chronic myeloid K562 cells were routinely maintained in the RPMI medium supplemented 
with 10% fetal bovine serum, 100 μg/mL of kanamycin, and 0.44 mg/mL of glutamine at 37 °C in a 
humidified atmosphere containing 5% CO2. 
3.4. WST-8 Assay to Determine K562 Cell Growth 
Cell viability was determined using the WST-8 assay kit as described previously by us [11,13] with 
a small modification. To investigate the effect of aaptamine on the growth of K562 cells, 0.1 mL of 
cells (8 × 10
3 cells/well) was seeded in 96-well plate in RPMI medium at 37 °C in a humidified 
atmosphere containing 5% CO2. Twenty four hours later, 0.5 μL of various stock solutions of aaptamine Int. J. Mol. Sci. 2011, 12  7357 
 
 
was added to achieve different final concentrations. After further incubation for 48 h at 37 °C, 10 μL of 
WST-8 was added to each well and the cells were further incubated at 37 °C. Three hours later, the 
absorbances at 450 nm and 650 nm (background) were measured with a microplate spectrophotometer. 
The number of viable cells remaining after the treatment was calculated using the following formula: 
Cell number (% control) = 100 × (absorbance of a given sample—absorbance  of Blank 
well)/(absorbance of Control well  –  absorbance of Blank well), where the Blank well contained 
medium only and the Control well contained cells without aaptamine. The GI50 value was calculated 
by fitting the data points to a logistic curve using the GraphPad Prism 4 software.  
3.5. Flow Cytometric Analysis of Cell Cycle 
The suspension (2 × 10
5 cells/2 mL/well) of K562 cells was placed in an 8-well plate and incubated 
for 24 h at 37 °C under a 5% CO2 atmosphere. Various concentrations of aaptamine (0, 20, 100 μM) 
were added and further incubated for 48 h. Then the cells were harvested and washed twice with cold 
PBS. The cells were then dyed with DNA-Prep Reagents Kit for 20 min. After centrifugation at 1000 × g, 
the supernatant was removed. 500 μL of PBS was added to the cell pellet, and the cell suspension was 
filtered with a 40 μm nylon mesh filter for cell cycle analysis. The analysis was carried out by flow 
cytometer  (FACS  Calibur,  Beckton  Dickinson,  λex  =  493  nm,  λem  = 630  nm)  and  quantified  by 
ModFit Software. 
3.6. Western Blot Analysis 
The cell suspension (1 × 10
6 cells/8 mL) of K562 cells was incubated with 100 μM of aaptamine for 
the indicated times under a 5% CO2 atmosphere at 37 °C. The cells were harvested and treated with 
lysis buffer (50 mM Tris-HCl, pH 7.2; 1% NP-40; 0.25% sodium deoxycholate; 150 mM NaCl; 1 mM 
EDTA; 1 mM PMSF; 1% proteinase inhibitor cocktail) to furnish a cell lysate. Protein assay was 
carried out by Bio-Rad protein assay kit. After boiling at 95 °C for 5 min in the sample buffer   
(0.125 M Tris-HCl, pH 6.8; 10% 2-mercaptoethanol; 4% SDS; 10% sucrose; 5% bromophenol blue), 
the equal amounts of protein were subjected to SDS-polyacrylamide gel electrophoresis (SDS-PAGE) 
and then transferred to PVDF membrane. The membrane was blocked with 5% milk TBS (Tween 
PBS), exposed to anti-Cip1/WAF-1/p21 or anti-β-actin and then to the anti-mouse HRP-conjugated 
antibody. The bound antibody was finally visualized by Enhanced Chemiluminescence (ECL) system.  
3.7. Transfection of K562 Cells and Luciferase Assay  
K562 cells were transfected with a human wild-type p21 promoter luciferase fusion plasmid pWWP 
by DEAE-Dextran (CellPhect Transfection Kit, Amersham Pharmacia Biotech, Uppsala, Sweden) as 
described by us previously [7]. The cells were incubated at a density of 5 × 10
4 cells/mL in a 12-well 
plate for 24 h. Then transfection was performed by adding pWWP and incubating for 15 min. The 
transfected cells were further incubated for 24 h followed by treatment with various concentrations of 
aaptamine for another 24 h. Finally, the cells were collected for luciferase assay using the luciferase 
assay system (E1501, Promega,  Madison, USA)  as we reported [7],  and  the luminescence was 
measured by using MICRO LUMAT Plus LB96V luminometer  and WING LOW software. The Int. J. Mol. Sci. 2011, 12  7358 
 
 
activation of p21 promoter was evaluated by the relative light intensity compared with that of the 
control (cells treated with DMSO only).  
4. Conclusions 
Aaptamine, an alkaloid isolated from the marine sponge of Aaptos suberitoides, inhibited growth of 
K562 cells, arrested cell cycle at G2/M phase, and transactivated p21 promoter in a p53-independent 
manner. We noted that aaptamine was recently reported to inhibit proteasome, while this activity was 
shown to be unrelated to the antiproliferative effect [16]. To our knowledge, our study is the first 
report about the antiproliferative activity of aaptamine on CML cells.  To further demonstrate the 
antiproliferative effect of aaptamine on CML cells, activities on other CML cell lines such as KYO-1 
and KCL-22 need to be tested. We also determined the antiproliferative activity of aaptamine on some 
other cancer cell lines such as A549 (lung cancer) and PC-3 (prostate cancer) with the GI50 as 7 and  
10 μM, respectively, suggesting that the antiproliferative effect of aaptamine is not specific to CML 
cells. While aaptamine might not become an anticancer drug itself, it might be used as a chemical tool 
to investigate the p21-related biology.  
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